DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Lucanthone

Lucanthone

  • Restoration of Temozolomide Sensitivity by PARP Inhibitors In

    Restoration of Temozolomide Sensitivity by PARP Inhibitors In

  • Table of Contents

    Table of Contents

  • Induction of Concentration-Dependent Blockade in the G2 Phase of the Cell Cycle by Cancer Chemotherapeutic Agents1

    Induction of Concentration-Dependent Blockade in the G2 Phase of the Cell Cycle by Cancer Chemotherapeutic Agents1

  • WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T

    WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T

  • Predicting Potential Drugs for Breast Cancer Based on Mirna and Tissue Specificity

    Predicting Potential Drugs for Breast Cancer Based on Mirna and Tissue Specificity

  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

  • Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity

    Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity

  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

  • Versitat Munster. the Production of Single Strand Breaks

    Versitat Munster. the Production of Single Strand Breaks

  • 2014 Annual Report

    2014 Annual Report

  • Protocol Update #09 ALLIANCE for CLINICAL TRIALS in ONCOLOGY

    Protocol Update #09 ALLIANCE for CLINICAL TRIALS in ONCOLOGY

  • Predicting Potential Treatments for Complex Diseases Based on Mirna and Tissue Specificity

    Predicting Potential Treatments for Complex Diseases Based on Mirna and Tissue Specificity

  • Polymerase Inhibitors in Mismatch Repair Deficient Glioblastoma Is Independent of Base Excision

    Polymerase Inhibitors in Mismatch Repair Deficient Glioblastoma Is Independent of Base Excision

  • (12) United States Patent (10) Patent No.: US 8,512,679 B2 Hyde Et Al

    (12) United States Patent (10) Patent No.: US 8,512,679 B2 Hyde Et Al

  • United States Patent (10) Patent No.: US 9,605,003 B2 Castro Et Al

    United States Patent (10) Patent No.: US 9,605,003 B2 Castro Et Al

  • Studies on the Selectivity of Antitumor Agents1 S

    Studies on the Selectivity of Antitumor Agents1 S

  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

  • (12) United States Patent (Lo) Patent No.: �US 8,480,637 B2

    (12) United States Patent (Lo) Patent No.: US 8,480,637 B2

Top View
  • WO 2010/091198 Al
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
  • Ev7n3p47.Pdf (530.0Kb)
  • Wo 2010/095940 A2
  • Customs Tariff - Schedule Xxi - 1
  • (12) United States Patent (10) Patent No.: US 9,512,107 B2 Cianchetta Et Al
  • Table S1. Full Ksrepo Results for GSE58477 and GSE63409
  • Harmonized Tariff Schedule of the United States (2006) (Rev
  • Mesh Terms for 2002
  • WO 2U11/132171 Al
  • Apurinic/Apyrimidinic Endonuclease Activity Is Associated With
  • (12) United States Patent (10) Patent No.: US 8,480,637 B2 Ferrari Et Al
  • ICD-10-CM TABLE of DRUGS and CHEMICALS
  • WO 2014/145606 Al 18 September 2014 (18.09.2014) P O P C T
  • Medicines & Vaccines in Development for Cancer
  • ICD-10-CM Table of Drugs 2019
  • Effect of Dihydroxyanthraquinoneand Radiationon G2progre@Sion1
  • (12) United States Patent (10) Patent No.: US 7,026,360 B1 Fest0 (45) Date of Patent: Apr


© 2024 Docslib.org    Feedback